Pricing
  1. JP-listed companies
  2. TAKARA BIO INC.
  3. Financials
  4. Pretax margin (%)

TAKARA BIO INC.【JP:4974】

Market cap
¥138.1B
P/E ratio
-15.3x
Takara Bio develops and manufactures biotechnology products including research reagents, PCR instruments, and gene therapy treatments for universities, research institutions, and companies worldwide.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndPretax margin (%) YoY (%)
Mar 31, 20255.8-26.47%
Mar 31, 20247.8-70.43%
Mar 31, 202326.5-37.04%
Mar 31, 202242+36.83%
Mar 31, 202130.7+67.31%
Mar 31, 202018.4+16.17%
Mar 31, 201915.8+32.28%
Mar 31, 201811.9-1.93%
Mar 31, 201712.2+9.73%
Mar 31, 201611.1+4.02%
Mar 31, 201510.7+13.91%
Mar 31, 20149.4-1.94%
Mar 31, 20139.6+2.28%
Mar 31, 20129.3

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)